Efficacy and safety of obinutuzumab in patients with primary membranous nephropathy: a focus on refractory and rituximab-resistant patients - Scorecard - MDSpire
Advertisement
Efficacy and safety of obinutuzumab in patients with primary membranous nephropathy: a focus on refractory and rituximab-resistant patients
Clinical Scorecard: Effectiveness and safety of obinutuzumab in individuals with primary membranous nephropathy: emphasis on patients resistant to rituximab and those with refractory cases
At a Glance
Category
Detail
Condition
Primary Membranous Nephropathy (PMN)
Key Mechanisms
Obinutuzumab is a humanised anti-CD20 monoclonal antibody that enhances B-cell depletion compared to rituximab.
Target Population
Patients with primary membranous nephropathy, including those resistant to rituximab and refractory cases.
Care Setting
Clinical treatment of nephrotic syndrome.
Key Highlights
95.74% of PMN patients achieved clinical remission after 24 months of obinutuzumab therapy.
100% clinical remission rate in the Initial therapy group.
Obinutuzumab demonstrated efficacy in refractory and rituximab-resistant patients.
68.4% of patients attained complete immunological remission following treatment.
The treatment showed an acceptable safety profile.
Guideline-Based Recommendations
Diagnosis
Diagnosis of PMN is based on clinical presentation and serological markers, including anti-PLA2R antibodies.
Management
Immunosuppressive therapy with glucocorticoid rescue therapy and alkylating agents is recommended as first-line treatment.
Monitoring & Follow-up
Monitor clinical remission rates and adverse events during treatment.
Risks
Traditional therapies are associated with significant toxic side effects, including severe infections and nephrotoxicity.
Patient & Prescribing Data
Patients with primary membranous nephropathy, including those with refractory cases.
Obinutuzumab may be a viable alternative for patients who do not respond to rituximab.
Clinical Best Practices
Consider obinutuzumab for patients with refractory PMN or those resistant to rituximab.
Regularly assess anti-PLA2R antibody levels to evaluate treatment response.
Preoperative use was associated with fewer revisions and no increase in short-term complications among patients with obesity, although benefits appeared concentrated in select subgroups.
